Pharmacopeia

CWP-0170

Misoprostol

Obstetric & Reproductive · Level 3

Core pharmacology

Class Group

Synthetic prostaglandin E1 (PGE1) analogue; gastric mucosal cytoprotectant and uterotonic.

Main Action

Reduces gastric acid secretion and promotes mucosal protection; stimulates uterine smooth-muscle contraction and cervical ripening.

Mechanism of action

Prostaglandin receptor activation inhibits acid secretion in gastric parietal cells and promotes mucosal defence; uterine prostanoid receptors stimulate contraction and cervical change.

Indications Uses

Australian Cytotec label: treatment of gastric/duodenal ulcer, NSAID-associated ulcer prevention and prevention of postoperative stress-related upper GI mucosal injury in specified ICU patients. In obstetric practice, misoprostol is used in selected induction/abortion/postpartum haemorrhage protocols, with indication and route dependent on local guidelines.

Route And Dose

Oral 200 microgram tablets for gastric indications (regimens vary). Obstetric doses and routes differ substantially and require indication-specific protocols; do not substitute gastrointestinal doses for obstetric dosing.

Metabolism

Converted to pharmacologically active misoprostol acid following administration.

Adverse Effects Toxicity

Diarrhoea, abdominal cramping, nausea, vomiting, fever/chills. Uterine tachysystole, haemorrhage and uterine rupture are important obstetric risks; prior uterine surgery increases concern.

Special Points

The Australian Cytotec gastrointestinal product information lists pregnancy as a contraindication because of uterotonic/abortifacient effects. That does NOT prohibit separate protocol-directed obstetric use: distinguish the registered gastrointestinal indication from professional obstetric indications, products and specialist supervision.

Source references

These October 2026 additions were reconciled against the linked sources. Refer to current local formulary guidance for clinical prescribing.